Overview
Journal for ImmunoTherapy of Cancer, published by BMJ (United Kingdom), published 9,771 papers in 2021–2025, and these papers have received 160,347 citations so far. Its h-index is 185 and its two-year mean citedness is 3.89. On the ITS Journal Score it ranks #1,174 of 62,158 ranked journals and #171 of 8,758 in Medicine.
Key figures
Citations are those received so far by the papers published in these years, so the most recent years have had less time to collect them. Two-year mean citedness is OpenAlex's measure of how often recent papers are cited; it is similar in idea to, but not the same as, an impact factor. Citation impact trend compares how often a journal's 2024-25 papers are cited with how often its 2021-22 papers were cited, each measured against all ranked journals' papers of the same years, so newer papers are not at a disadvantage. "Not enough papers" or "Not enough data" means fewer than 50 papers in one of the two-year periods (or fewer than 50 citations to the earlier papers). Values above +300% or below -90% are shown as "+300% or more" or "-90% or less": such extreme values come from very low citation counts for the earlier papers.
Papers and citations by year
| Year | Papers | Citations so far to that year's papers | Open-access papers |
|---|---|---|---|
| 2020 | 1,521 | 13,089 | 1,521 |
| 2021 | 1,609 | 21,231 | 1,609 |
| 2022 | 2,088 | 27,837 | 2,088 |
| 2023 | 2,065 | 32,481 | 2,065 |
| 2024 | 1,969 | 37,238 | 1,969 |
| 2025 | 2,040 | 41,560 | 2,040 |
What it publishes
The leading research topics of its papers (OpenAlex topic classification). Select a topic to find other journals that publish on it.
Similar journals
Ranked journals that publish on the same topics.
| Journal | Field | Score | Papers 2021–2025 | Open access |
|---|---|---|---|---|
| Cancer Immunology Immunotherapy | Immunology and Microbiology | 83.7 | 1,451 | 100% |
| Journal of Immunotherapy | Medicine | 69.8 | 240 | 35% |
| Journal of Cancer Immunology | Medicine | 48.2 | 90 | 98% |
| OncoImmunology | Immunology and Microbiology | 82.9 | 796 | 100% |
| Immunotherapy | Immunology and Microbiology | 71.9 | 664 | 48% |
| Cancer Immunology Research | Medicine | 76.7 | 1,553 | 32% |
| Immuno-Oncology Technology | Medicine | 52.7 | 1,180 | 100% |
| Journal of Immunotherapy and Precision Oncology | Medicine | 60.4 | 151 | 100% |
Compare with similar journals (side by side with the two closest journals above)
Identity and sources
- ISSN-L: 2051-1426
- Print ISSN: 2051-1426
- Publisher: BMJ
- Listed in DOAJ: Yes (checked against DOAJ)
- Crossref: ISSN found in Crossref
- OpenAlex: S2754803477
- Journal website: jitc.bmj.com
Figures come from OpenAlex (papers, citations, h-index, topics), Crossref (ISSN check) and DOAJ (open-access listing and fees). They change as records are corrected, so treat them as a dated snapshot. This page does not state whether the journal is indexed in Scopus, Web of Science or PubMed.
Questions
What is the ITS Journal Score of Journal for ImmunoTherapy of Cancer?
It is 83.3 out of 100, which places it #1,174 among ranked journals. The score combines citation impact (45%), h-index (35%) and size (20%) from open OpenAlex data.
What is the impact factor of Journal for ImmunoTherapy of Cancer?
This site does not publish Journal Impact Factors, which belong to Clarivate. As an open alternative, its two-year mean citedness in OpenAlex is 3.89.
Is Journal for ImmunoTherapy of Cancer open access?
100% of its papers from 2021–2025 are recorded as open access, and it is listed in DOAJ.
Does Journal for ImmunoTherapy of Cancer charge a publication fee?
DOAJ records an article processing charge of 2,390 GBP. Check the journal's website for the current fee and any waivers.